Evidence map›Paper›PMID 34647442›Full record

Trial reportHaematologica2022

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.

Nigel H Russell, Robert K Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Mike Dennis, Charles Craddock, Sylvie Freeman, Richard E Clark, Alan K Burnett

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Nigel H RussellDepartment of Haematology, Nottingham University Hospitals. nigel.russell@notingham.ac.uk.
Robert K HillsNuffield Department of Population Health, University of Oxford.
Abin ThomasCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University.
Ian ThomasCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University.
Lars KjeldsenDepartment of Haematology, Rigshospitalet, Copenhagen.
Mike DennisDepartment of Haematology, Christie Hospital.
Charles CraddockDepartment of Haematology, Queen Elizabeth Hospital.
Sylvie FreemanDepartment of Immunology and Immunotherapy, University of Birmingham.
Richard E ClarkDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool.
Alan K BurnettBlackwaterfoot, Isle of Arran.
Cardiff University · GBAltran (United Kingdom) · GBNottingham University Hospitals NHS Trust · GBRigshospitalet · DKThe Christie Hospital · GBUniversity of Birmingham · GBUniversity of Liverpool · GBUniversity of Oxford · GB

Funding

Cancer Research UK 25350Cancer Research UK A6031
6 · The paper itself

Abstract

Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk patients aged 35-65 years. We here present analyses from the NCRI AML16 trial extending this experience to older patients aged 60-70 inclusive lacking favorable-risk cytogenetics. Nine hundred thirty-two patients were studied, with RIC transplant in first remission given to 144 (sibling n=52, matched unrelated donor n=92) with a median follow-up for survival from complete remission of 60 months. Comparisons of outcomes of patients transplanted versus those not were carried out using Mantel-Byar analysis. Among the 144 allografted patients, 93 had intermediate-risk cytogenetics, 18 had adverse risk and cytogenetic risk group was unknown for 33. In transplanted patients survival was 37% at 5 years, and while the survival for recipients of grafts from siblings (44%) was better than that for recipients of grafts from matched unrelated donors (34%), this difference was not statistically significant (P=0.2). When comparing RIC versus chemotherapy, survival of patients treated with the former was significantly improved (37% versus 20%, hazard ratio = 0.67 [0.53-0.84]; P<0.001). When stratified by Wheatley risk group into good, standard and poor risk there was consistent benefit for RIC across risk groups. When stratified by minimal residual disease status after course 1, there was consistent benefit for allografting. The benefit for RIC was seen in patients with a FLT3 ITD or NPM1 mutation with no evidence of a differential effect by genotype. We conclude that RIC transplantation is an attractive option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics and, in this study, we could not find a group that did not benefit.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival AnalysisTransplantation Conditioning

Identifiers

PMID34647442
PMCPMC9244837
OpenAlexW3207458111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.